walking most far sighted V-Max 50 Generic Name: virginiamycin powder Dosage Form: FOR ANIMAL USE ONLY V-Max TM 50 (Virginiamycin) TYPE A MEDICATED ARTICLE To be mixed in cattle feed Active Drug Ingredient Virginiamycin : 11% (Contains 50 g virginiamycin activity per lb) Inert ingredients : Processed grain by-products, roughage products, calcium carbonate, carboxymethylcellulose, mineral oil Important: Must be diluted in feed before use Follow Directions on Back Panel For use in complete feeds for cattle fed in confinement for slaughter as specified below Directions for Use Cattle fed in confinement for slaughter Virginiamycin required mg/hd/day Virginiamycin (g/tons) of complete feed (90% dry matter basis) Improved feed efficiency 70 240 11.0 16.0 Reduction of incidence of liver abscesse 85 240 13.5 16.0 Increased rate of weight gain 100 340 16.0 22.5 Caution: Not for use in animals intended for breeding. Mixing Directions Type B Medicated Feeds for cattle fed in confinement for slaughter Thoroughly mix the following amounts of V-Max 50 Type A Medicated Article to make 1 ton of Type B Medicated Feed to provide the concentrations shown in Table 1. An intermediate blending step, consistent with the mixing equipment specifications, should be performed to ensure adequate mixing. Table 1. Type B Medicated Feed lb of V-Max 50 Type A Medicated Article per ton of supplement Virginiamycin concentration in Type B Medicated Feed (g/ton) 5 10 20 40 100 200 250 500 1,000 2,000 5,000 10,000 Preparation of Type C Medicated Feed for cattle fed in confinement for slaughter: From Type B Medicated Feed: The Type B Medicated Feed must be diluted to a Type C Medicated Feed before being fed. Prepare a Type B Medicated Feed as described above. Thoroughly mix the V-Max 50 Type B Medicated Feed to make 1 ton of Type C Medicated Feed to provide 11.0 22.5 g of virginiamycin per ton of complete feed on a 90% dry matter basis using the examples provided in Table 2. Table 2. Type C Medicated Feed lb of a 500g/ton Type B Medicated Feed per ton of complete feed lb of a 1,000 g/ton Type B Medicated Feed per ton of complete feed lb of a 5,000 g/ton Type B Medicated Feed per ton of complete feed lb of a 10,000 g/ton Type B Medicated Feed per ton of complete feed Virginiamycin concentration in complete feed 90% dry matter basis (g/ton) 44 22 4.4 2.2 11.0 54 27 5.4 2.7 13.5 64 32 6.4 3.2 16.0 90 45 9.0 4.5 22.5 From Type A Medicated Article: V-Max 50 Type A Medicated Article must be diluted to a Type C Medicated Feed before being fed. Thoroughly mix the Type A Medicated Article to make 1 ton of Type C Medicated Feed to provide 11.0 22.5 g of virginiamycin per ton of complete feed on a 90% dry matter basis using the examples provided in Table 3. An intermediate blending step, consistent with the blending equipment specifications, should be performed to ensure adequate mixing. Table 3. Type C Medicated Feed prepared from V-Max 50 Type A Medicated Article lb of V-Max 50 Type A Medicated Article per ton of complete feed Virginiamycin concentration in complete feed 90% dry matter basis (g/ton) 0.22 0.27 0.32 0.45 11.0 13.5 16.0 22.5 Feed continuously as sole ration Store at or Below 25 C/77F , Excursions Permitted Up To 40 o C (104 o F) Close container after use NOT FOR HUMAN USE RESTRICTED DRUG (CALIFORNIA) USE ONLY AS DIRECTED NADA #140-998, Approved by FDA 8812000 101-9141-01 NET CONTENTS: 50 lb (22.7 kg) Distributed by: PHIBRO ANIMAL HEALTH, INC. 65 Challenger Road Ridgefield Park, NJ 07660, USA V-Max 50 virginiamycin powder Product Information Product Type OTC TYPE A MEDICATED ARTICLE ANIMAL DRUG Item Code (Source) NDC:66104-9601 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength VIRGINIAMYCIN (VIRGINIAMYCIN) VIRGINIAMYCIN 227 g in 0.45 kg Inactive Ingredients Ingredient Name Strength CALCIUM CARBONATE MINERAL OIL CARBOXYMETHYLCELLULOSE SODIUM Packaging # Item Code Package Description 1 NDC:66104-9601-1 22.7 kg in 1 BAG Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NADA NADA140998 04/01/2010 Labeler - Phibro Animal Health (006989008) Revised: 04/2009 Phibro Animal Health Print this page FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Recently Approved Lonhala Magnair Lonhala Magnair (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) bronchodilator for... Ozempic Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the... Ogivri Ogivri (trastuzumab-dkst) is a HER2 / neu receptor antagonist biosimilar to Herceptin indicated for... Sublocade Sublocade (buprenorphine) is a once-monthly injectable partial opioid agonist formulation for the... More it's your decision
large V-Max 50 sufficiently subtle
EmoticonEmoticon